{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:49:58Z","timestamp":1760852998434},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1016\/j.bcp.2004.03.004","type":"journal-article","created":{"date-parts":[[2004,5,29]],"date-time":"2004-05-29T17:35:36Z","timestamp":1085852136000},"page":"239-251","source":"Crossref","is-referenced-by-count":24,"title":["Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR)\u03b1 activator, in non-human primates"],"prefix":"10.1016","volume":"68","author":[{"given":"Silke A","family":"Sch\u00e4fer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara C","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"V\u00f6lkl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.Dariush","family":"Fahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Pill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2004.03.004_BIB1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev.biochem.68.1.559","article-title":"Nuclear-receptor ligands and ligand-binding domains","volume":"68","author":"Weatherman","year":"1999","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bcp.2004.03.004_BIB2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1749-6632.2002.tb04258.x","article-title":"PPARs: transcription factors controlling lipid and lipoprotein metabolism","volume":"967","author":"Bocher","year":"2002","journal-title":"Ann N.Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2004.03.004_BIB3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/ajcn\/70.4.566","article-title":"Peroxisome proliferator-activated receptors: a family of lipid-activated transcription factors 1\u20134","volume":"70","author":"Clarke","year":"1999","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.bcp.2004.03.004_BIB4","first-page":"649","article-title":"Peroxisome proliferator-activated receptors: nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bcp.2004.03.004_BIB5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00060793-200002000-00002","article-title":"Peroxisome proliferator-activated receptors (PPARs) and their implications in diseases","volume":"7","author":"Vamecq","year":"2000","journal-title":"Curr. Opin. Endocrinol. Diabet."},{"key":"10.1016\/j.bcp.2004.03.004_BIB6","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/019262301317052495","article-title":"Peroxisome proliferator-activated receptors in atherosclerosis and inflammation-an update","volume":"29","author":"Elangbam","year":"2001","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.bcp.2004.03.004_BIB7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00041433-200002000-00002","article-title":"Omega-3 polyunsaturated fatty acid regulation of gene expression","volume":"11","author":"Price","year":"2000","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.bcp.2004.03.004_BIB8","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0022-2275(20)42003-6","article-title":"Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression","volume":"37","author":"Schoonjans","year":"1996","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bcp.2004.03.004_BIB9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0006-2952(02)01157-7","article-title":"Is there a single mechanism for fatty acid regulation of gene transcription?","volume":"64","author":"Duplus","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2004.03.004_BIB10","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2004.03.004_BIB11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0163-7258(02)00232-2","article-title":"Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis","volume":"95","author":"Vosper","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2004.03.004_BIB12","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(00)90002-3","article-title":"Thiazolidinediones: an update","volume":"355","author":"Schoonjans","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2004.03.004_BIB13","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0006-2952(01)00764-X","article-title":"Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-\u03b3 (PPAR\u03b3)-independent, antioxidant-related mechanism","volume":"62","author":"Davies","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2004.03.004_BIB14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1749-6632.1996.tb18620.x","article-title":"Peroxisome proliferator-activated receptors: structures and function","volume":"804","author":"Tugwood","year":"1996","journal-title":"Ann N.Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2004.03.004_BIB15","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1073\/pnas.091021198","article-title":"A selective peroxisome proliferator-activated receptor \u03b4 agonist promotes reverse cholesterol transport","volume":"98","author":"Oliver","year":"2001","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2004.03.004_BIB16","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2337\/diab.46.8.1319","article-title":"Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients","volume":"46","author":"Auboeuf","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2004.03.004_BIB17","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0022-2275(20)32207-0","article-title":"Effects of fenofibrate on lipid parameters in obese rhesus monkeys","volume":"42","author":"Winegar","year":"2001","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bcp.2004.03.004_BIB18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0005-2760(96)00066-5","article-title":"The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation","volume":"1302","author":"Schoonjans","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2004.03.004_BIB19","doi-asserted-by":"crossref","unstructured":"Martin G, Schoonjans K, Staels B, Auwerx J. PPAR activators improve glucose homeostasis by changing fatty acid partitioning. In: Jacotot B, Math\u00e9 D, Fruchart JC, editors. Atherosclerosis XI. Singapore: Elsevier Science; 1998. p. 35\u201347.","DOI":"10.1016\/S0021-9150(97)00315-8"},{"key":"10.1016\/j.bcp.2004.03.004_BIB20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(03)00269-1","article-title":"Peroxisome-proliferator-activated receptor \u03b4 activates fat metabolism to prevent obesity","volume":"113","author":"Wang","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2004.03.004_BIB21","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0223-5234(99)80029-4","article-title":"\u03c9-Substituted alkyl carboxylic acids as antidiabetic and lipid-lowering agents","volume":"33","author":"Meyer","year":"1998","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2004.03.004_BIB22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s002040050633","article-title":"Species differences in induction of hepatic enzymes by BM 17.0744, an activator of peroxisome proliferator-activated receptor alpha (PPAR\u03b1)","volume":"73","author":"Meyer","year":"1999","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bcp.2004.03.004_BIB23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00210-001-0504-z","article-title":"Pharmacological analysis of wild-type \u03b1, \u03b3 and \u03b4 subtypes of the human peroxisome proliferator-activated receptor","volume":"365","author":"Wurch","year":"2002","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.bcp.2004.03.004_BIB24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0026-0495(99)90007-0","article-title":"BM 17.0744: a structurally new antidiabetic compound with insulin-sensitizing and lipid-lowering activity","volume":"48","author":"Pill","year":"1999","journal-title":"Metabolism"},{"key":"10.1016\/j.bcp.2004.03.004_BIB25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1527-3466.1999.tb00018.x","article-title":"Reduction of risk factors for cardiovascular complications by BM 17.0744","volume":"17","author":"Pill","year":"1999","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.bcp.2004.03.004_BIB26","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1172\/JCI111533","article-title":"Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects","volume":"74","author":"Bogardus","year":"1984","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2004.03.004_BIB27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1042\/bj2270205","article-title":"A sensitive spectrophotometric assay for peroxisomal acyl-CoA oxidase","volume":"227","author":"Small","year":"1985","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2004.03.004_BIB28","first-page":"383","article-title":"Selective induction of peroxisomal enzymes by the hypolipidemic drug bezafibrate. Detection of modulations by automatic image analysis in conjunction with immunoelectron microscopy and immunoblotting","volume":"46","author":"Beier","year":"1988","journal-title":"Eur. J. Cell Biol."},{"issue":"259","key":"10.1016\/j.bcp.2004.03.004_BIB29","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2004.03.004_BIB30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0003-2697(81)90281-5","article-title":"\u201cWestern blotting\u201d: electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A","volume":"112","author":"Burnette","year":"1981","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.bcp.2004.03.004_BIB31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0165-022X(84)90040-X","article-title":"Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose","volume":"10","author":"Kyhse-Andersen","year":"1984","journal-title":"J. Biochem. Biophys. Methods"},{"key":"10.1016\/j.bcp.2004.03.004_BIB32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF02473205","article-title":"Contributions of the immunogold technique to investigation of the biology of peroxisomes","volume":"106","author":"Fahimi","year":"1996","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.bcp.2004.03.004_BIB33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/jemt.1070210404","article-title":"Application of automatic image analysis for quantitative morphological studies of peroxisomes in rat liver in conjunction with cytochemical staining with 3-3\u2032-diaminobenzidine and immunocytochemistry","volume":"21","author":"Beier","year":"1992","journal-title":"Microsc. Res. Tech."},{"key":"10.1016\/j.bcp.2004.03.004_BIB34","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1055\/s-2003-43510","article-title":"The effects of K-111, a new insulin-sensitizer, on metabolic syndrome in obese prediabetic rhesus monkeys","volume":"35","author":"Bodkin","year":"2003","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.bcp.2004.03.004_BIB35","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s001250051193","article-title":"The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction","volume":"42","author":"Lenhard","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2004.03.004_BIB36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: from orphan receptors to drug discovery","volume":"43","author":"Willson","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2004.03.004_BIB37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7326\/0003-4819-131-4-199908170-00008","article-title":"Pharmacologic therapy for type 2 diabetes mellitus","volume":"131","author":"DeFronzo","year":"1999","journal-title":"Ann. Int. Med."},{"key":"10.1016\/j.bcp.2004.03.004_BIB38","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1046\/j.1464-5491.2002.00734.x","article-title":"Combination of insulin and thiazolidinedione therapy in massively obese patients with type 2 diabetes","volume":"19","author":"Buch","year":"2002","journal-title":"Diabet. Med."},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2004.03.004_BIB39","first-page":"A98","article-title":"Improved glycemic control and no weight gain in Mexican patients treated with rosiglitazone 4 mg per day in combination with metformin","volume":"51","author":"Gould","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2004.03.004_BIB40","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","article-title":"Role of insulin resistance in human disease","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2004.03.004_BIB41","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1172\/JCI117518","article-title":"Metabolic and genetic characterization of prediabetic states, sequence of events leading to non-insulin-dependent diabetes mellitus","volume":"94","author":"Beck-Nielsen","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2004.03.004_BIB42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1365-2710.2003.00482.x","article-title":"Insulin resistance\u2014the new goal","volume":"28","author":"Peter","year":"2003","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.bcp.2004.03.004_BIB43","first-page":"263","article-title":"Dyslipidemia in non-insulin-dependent diabetes mellitus","volume":"15","author":"Howard","year":"1994","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bcp.2004.03.004_BIB44","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1042\/cs0900243","article-title":"Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases?","volume":"90","author":"Frayn","year":"1996","journal-title":"Clin. Sci."},{"key":"10.1016\/j.bcp.2004.03.004_BIB45","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.2337\/diabetes.51.2007.S295","article-title":"Genetics of obesity and type 2 diabetes. Tracking pathogenic traits during the predisease period","volume":"51","author":"Bougn\u00e8res","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2004.03.004_BIB46","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2337\/diabetes.48.6.1217","article-title":"Activators of peroxisome proliferator-activated receptor-alpha induce the expression of the uncoupling protein-3 gene in skeletal muscle: a potential mechanism for the lipid intake-dependent activation of uncoupling protein-3 gene expression at birth","volume":"48","author":"Brun","year":"1999","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2004.03.004_BIB47","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.1038\/oby.2002.202","article-title":"The obesity epidemic: pathophysiology and consequences of obesity","volume":"10","author":"Pi-Sunyer","year":"2002","journal-title":"Obes. Res."},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2004.03.004_BIB48","doi-asserted-by":"crossref","first-page":"116S","DOI":"10.1038\/oby.2002.204","article-title":"Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options","volume":"10","author":"Fujioka","year":"2002","journal-title":"Obes. Res."},{"key":"10.1016\/j.bcp.2004.03.004_BIB49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature01921","article-title":"Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR\u03b1","volume":"425","author":"Fu","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2004.03.004_BIB50","unstructured":"Fahimi HD, Baumgart E, Beier K, Pill J, Hartig F, V\u00f6lkl A. Ultrastructural and biochemical aspects of peroxisome proliferation and biogenesis in different mammalian species. In: Gibson G, Lake B, editors. Peroxisomes: biology and importance in toxicology and medicine. London, Washington: Taylor and Francis; 1993. p. 395\u2013424."},{"key":"10.1016\/j.bcp.2004.03.004_BIB51","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0006-2952(66)90168-7","article-title":"Changes in the weight and composition of the liver in the rat, dog and monkey treated with ethyclorophenoxyisobutyrate","volume":"15","author":"Platt","year":"1966","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2004.03.004_BIB52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/074823378700300214","article-title":"Interspecies differences in peroxisomes and peroxisome proliferation","volume":"3","author":"Rodricks","year":"1987","journal-title":"Toxicol. Ind. Health"},{"key":"10.1016\/j.bcp.2004.03.004_BIB53","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1749-6632.1996.tb18649.x","article-title":"Peroxisome proliferators: species differences in response of primary hepatocyte cultures","volume":"804","author":"Elcombe","year":"1996","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2004.03.004_BIB54","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1021\/bi00072a015","article-title":"cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor","volume":"32","author":"Sher","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2004.03.004_BIB55","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1124\/mol.53.1.14","article-title":"Peroxisome proliferator activated receptor-\u03b1 expression in human liver","volume":"53","author":"Palmer","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2004.03.004_BIB56","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s002040050629","article-title":"Peroxisome proliferators: mechanisms of adverse effects in rodents and molecular basis for species differences","volume":"73","author":"Roberts","year":"1999","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bcp.2004.03.004_BIB57","doi-asserted-by":"crossref","first-page":"25713","DOI":"10.1074\/jbc.273.40.25713","article-title":"The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erb alpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates","volume":"273","author":"Vu-Dac","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2004.03.004_BIB58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0378-4274(99)00243-X","article-title":"Apoptosis and proliferation in nongenotoxic carcinogenesis: species differences and role of PPARalpha","volume":"112\/113","author":"Roberts","year":"2000","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.bcp.2004.03.004_BIB59","doi-asserted-by":"crossref","first-page":"13510","DOI":"10.1074\/jbc.275.18.13510","article-title":"Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR","volume":"275","author":"Zhu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2004.03.004_BIB60","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1074\/jbc.C200634200","article-title":"Coactivator PRIP, the peroxisome proliferator-activated receptor-interacting protein, is a modulator of placental, cardiac, hepatic, and embryonic development","volume":"278","author":"Zhu","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2004.03.004_BIB61","doi-asserted-by":"crossref","first-page":"11836","DOI":"10.1073\/pnas.182426699","article-title":"Identification of a transcriptionally active peroxisome proliferator-activated receptor \u03b1-interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator","volume":"99","author":"Surapureddi","year":"2002","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2004.03.004_BIB62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1515\/CCLM.2000.002","article-title":"Regulation of lipid and lipoprotein metabolism by PPAR activators","volume":"38","author":"Gervois","year":"2000","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.bcp.2004.03.004_BIB63","doi-asserted-by":"crossref","first-page":"24484","DOI":"10.1074\/jbc.M202449200","article-title":"WY14,643, a peroxisome proliferator-activated receptor alpha (PPAR alpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP\/F-1 mice","volume":"277","author":"Chou","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2004.03.004_BIB64","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/01.ATV.0000015598.86369.04","article-title":"Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis","volume":"22","author":"Barbier","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295204001790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295204001790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T17:19:03Z","timestamp":1624382343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295204001790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S0006295204001790"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2004.03.004","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}